Preethi Krishnan

Preethi Krishnan

Auto-generated profile, based on publicly available information

Preethi Krishnan

Researcher

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
JLJieh-Yuan Liou
Jieh-Yuan Liou
PKPreethi Krishnan
Preethi Krishnan
CHCheng-Chih Hsieh
Cheng-Chih Hsieh
GDGinger E. Dutschman
Ginger E. Dutschman
YCYung-Chi Cheng
Yung-Chi Cheng
Deoxycytidylate deaminase, catalyzing the conversion of dCMP to dUMP, is an important enzyme in the de novo synthesis of thymidine nucleotides. It also may be involved in the action, as well as the metabolism of anticancer agents. Recently, several l- and d-configuration pyrimidine deoxynucleoside analogs were found to be potent antiviral and antitumor agents. Their interaction with dCMP deaminase as a monophosphate or a triphosphate metabolite is not clear. These include d-nucleoside analogs such as β-d-2′,3′-dideoxycytidine (ddC), β-2′-fluoro-5-methyl-arabinofuranosyluracil (FMAU), 3′-azido-2′,3′-dideoxythymidine (AZT), and 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) as well asl-nucleoside analogs such as β-l-dioxolane-cytidine (l-OddC), β-l-2′,3′-dideoxy-3′-thiacytidine, β-l-2′,3′-dideoxy-5′-fluoro-3′-thia-cytidine (l-FSddC), β-l-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine, andl-FMAU. None of the l-deoxycytidine analog monophosphates act as substrates or inhibitors. Among these pyrimidine deoxynucleoside analog monophosphates, d-FMAU monophosphate (MP) is the most potent competitive inhibitor, whereasl-FMAUMP has no inhibitory activity. Interestingly, AZTMP and D4TMP also have potent inhibitory activities on dCMP deaminase. Among the dCTP and TTP analogs examined, d- andl-FMAUTP were the most potent inhibitors and had the same extent of inhibitory effect. These results suggest that a chiral specificity for the substrate-binding site may exist, but there is no chiral specificity for the regulator-binding site. This is also supported by the observation that l-OddC andl-FSddC have inhibitory activities as triphosphates but not as monophosphates. None of the d- and l-dCTP analogs activated dCMP deaminase as dCTP. The biological activities of AZT and D4T could be partially attributable to their inhibitory activity against dCMP deaminase by their phosphorylated metabolites, whereas that of ddC and the l-deoxycytidine analogs may not involve dCMP deaminase directly.

8 December 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
TNTeresa Ng
Teresa Ng
PDPatrick K. Dorr
Patrick K. Dorr
PKPreethi Krishnan
Preethi Krishnan
DCDaniel E. Cohen
Daniel E. Cohen
SRSusan Rhee
Susan Rhee
WKWarren M. Kati
Warren M. Kati
With the morbidity and mortality associated with the COVID‐19 pandemic that we are witnessing this year, the risks posed by emerging viral diseases to global health are all too obvious. This pandemic highlights the importance of antiviral drug discovery, which targets emerging viral pathogens, as well as existing pathogenic viruses that undergo continuous evolution. Drug discovery and development is a long and resource intensive process; however, the use of biomarkers can accelerate clinical development of antivirals by providing information regarding diagnosis of specific viral infections, status of infection, potential safety parameters, and antiviral responses. In clinical practice, many of the biomarkers initially utilized to support clinical development are also used for patient care. While viral load is a standard and essential biomarker used to detect the desired viral suppression induced by an antiviral agent, it has become apparent that additional biomarkers, whether related to the virus, the host or as a consequence of the drug's mechanistic effects, are also important for monitoring clinical outcomes associated with an antiviral therapy. This review summarizes the biomarkers used in the clinical development (as well as in clinical practice, where appropriate) of antiviral therapies for hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and severe acute respiratory syndrome coronavirus 2.

1 January 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
TNTeresa Ng
Teresa Ng
Liangjun LuLiangjun Lu
Liangjun Lu
TRT. Reisch
T. Reisch
PKP. Krishnan
P. Krishnan
GSG. Schnell
G. Schnell
CCC. Collins
C. Collins

1 January 2020 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AKA. Chris Krueger
A. Chris Krueger
HCHui-Ju Chen
Hui-Ju Chen
JRJohn T. Randolph
John T. Randolph
BBBrian S. Brown
Brian S. Brown
GHGeoff T. Halvorsen
Geoff T. Halvorsen
DDDavid A. DeGoey
David A. DeGoey

1 October 2023 in Physiological Measurement
Verified
Journal Article
Open access
PKPreethi Krishnan
Preethi Krishnan
MRMilad G Rad
Milad G Rad
PAPalak Agarwal
Palak Agarwal
CMCurtis Marshall
Curtis Marshall
PYPhilip Yang
Philip Yang
RKRishikesan Kamaleswaran
Rishikesan Kamaleswaran
Objective . To examine whether heart rate interval based rapid alert (HIRA) score derived from a combination model of heart rate variability (HRV) and modified early warning score (MEWS) is a surrogate for the detection of acute respiratory failure (ARF) in critically ill sepsis patients. Approach . Retrospective HRV analysis of sepsis patients admitted to Emory healthcare intensive care unit (ICU) was performed between sepsis-related ARF and sepsis controls without ARF. HRV measures such as time domain, frequency domain, and nonlinear measures were analyzed up to 24 h after patient admission, 1 h before the onset of ARF, and a random event time in the sepsis controls. Statistical significance was computed by the Wilcoxon Rank Sum test. Machine learning algorithms such as eXtreme Gradient Boosting and logistic regression were developed to validate the HIRA score model. The performance of HIRA and early warning score models were evaluated using the area under the receiver operating characteristic (AUROC). Main Results . A total of 89 (ICU) patients with sepsis were included in this retrospective cohort study, of whom 31 (34%) developed sepsis-related ARF and 58 (65%) were sepsis controls without ARF. Time-domain HRV for Electrocardiogram (ECG) Beat-to-Beat RR intervals strongly distinguished ARF patients from controls. HRV measures for nonlinear and frequency domains were significantly altered ( p < 0.05) among ARF compared to controls. The HIRA score AUC: 0.93; 95% confidence interval (CI): 0.88–0.98) showed a higher predictive ability to detect ARF when compared to MEWS (AUC: 0.71; 95% CI: 0.50–0.90). Significance . HRV was significantly impaired across patients who developed ARF when compared to controls. The HIRA score uses non-invasively derived HRV and may be used to inform diagnostic and therapeutic decisions regarding the severity of sepsis and earlier identification of the need for mechanical ventilation.

1 January 2016 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
PKPreethi Krishnan
Preethi Krishnan
MUMuralidharan
Muralidharan